07:45
Treatment of community-acquired pneumonia
07:45
EUCAST: frequently asked questions
07:45
Facilitating antimicrobial drug development: opportunities through the US NIH/NIAID and the EU research programmes
07:45
Diagnosis of carbapenemase producers in Enterobacteriaceae
07:45
Travel medicine - where is it going?
07:45
Vaccine recommendations in immunocompromised patients
07:45
Chronic respiratory fungal disease
07:45
Cost-efficient diagnosis of tuberculosis: culture, molecular techniques and immunological markers
09:00
Adaptation of P. aeruginosa to acute and chronic infections
09:00
Challenges in osteoarticular infections
09:00
Resistance to anti-Gram-positive agents in Europe
09:00
Diagnosing fungal diseases: future perspectives
09:00
Sequencing viruses - what can it tell us
09:00
Tuberculosis; epidemiology, diagnosis and management
09:00
Appropriate management of CA-RTIs- applying consensus principles for antibiotic therapy
09:00
Prevenar 13, the new generation
09:00
Trichomonas vaginalis - no longer a minor STD
09:00
Of money and bugs: the impact of recession on infectious diseases
11:30
Efflux and resistance - from basics to clinics
11:30
Adaptation of bacteria from the environmental lifestyle to the lifestyle in chronic infections
11:30
Nobel Laureate 2011 Keynote Lecture
11:30
Risk-based algorithms for antifungal use in ICU
11:30
Human papillomaviruses: recent advances
11:30
Is it important who you are when you get an infectious disease?
11:30
Epidemiology of MRSA in various European countries
11:30
Pathogenesis of viral infections
11:30
Novel methods to diagnose infections
11:30
Monitoring antibiotic prescriptions in primary care: what world do we discover?
12:30
POSTER SESSION II
12:30
Antibiotic use and antibiotic stewardship
12:30
Bacterial fitness and antibiotic resistance of Gram-negative bacteria
12:30
Emergence of bacterial resistance in humans, animals and the environment
12:30
Environmental control and health-care-associated infections
12:30
Clinical epidemiology of nosocomial infections - general
12:30
Clinical epidemiology of nosocomial infections - Gram-positive infections
12:30
Clinical epidemiology of nosocomial infections - Gram-negative infections
12:30
International and national resistance surveillance data
12:30
Highlights of the molecular bases of antimicrobial resistance in Enterobacteriaceae
12:30
Epidemiology and molecular antimicrobial resistance of Acinetobacter sp.
12:30
Epidemiology and molecular resistance of Staphylococcus sp. and Enterococcus sp.
12:30
Epidemiology of antimicrobial resistance
12:30
Epidemiology of MRSA, VRE and other Gram-positives
12:30
Genetics of antimicrobial resistance
12:30
Diagnosis and follow-up of syphilis
12:30
Diagnosis and prevention of device-associated infection
13:30
POSTER SESSION III
13:30
Molecular bacteriology: into the deep
13:30
Molecular diagnosis of bacterial infections
13:30
Molecular epidemiology of bacterial infections
13:30
Good to know: drug potency, purity, prescribing, errors and toxicity
13:30
New antibacterial agents under investigation
13:30
New antimicrobial agents against old and new protein targets
13:30
Tigecycline activity and resistance
13:30
Novel approaches in antimicrobial susceptibility testing
13:30
Novel methods for bacterial indentification and molecular detection of antimicrobial resistance - non-commercial methods
13:30
Resistance surveillance in defined clinical situations
13:30
Streptococcus pneumoniae - seroprevalence and antimicrobial resistance
13:30
Urinary tract infections
13:30
Tropical medicine
13:30
Pharmacodynamic analyses and antibiotic combinations: S.aureus, MDR-Klebsiella and others
13:30
New pharmacokinetic data
14:30
AFTERNOON SESSIONS
14:30
Cell wall targets and antibiotic winners and losers - an ecological dilemma
14:30
ESCMID Excellence Award lecture
14:30
Challenges in developing vaccines against malaria, HIV and HCV
14:30
Automated antimicrobial susceptibility testing systems; blessing or curse? - PRO/CON debate
14:30
The year in infectious diseases
14:30
Patient participation and empowerment in infection control - PRO/CON debate
14:30
Optimised pharmacotherapy for nosocomial and healthcare-associated infection
14:30
Antimicrobial resistance in the environment
14:30
Considering pharmacodynamic effects in antifungal treatment strategies
14:30
ICU infections
16:00
Reemergence of gonococcal infections
16:00
Non-mammalian models of infection
16:00
Genetic predisposition to fungal infection
16:00
Infection control beyond the hospital: do perspectives change?
16:00
Highlights of parasitic disease research
16:00
Antibiotic resistance in bloodstream and tissue infections
16:00
New perspectives on otitis media: implications of a multi‐pathogen environment
16:00
Smart Bugs: the MRSA nosocomial infection challenge with a focus on complicated skin and soft-tissue infection and nosocomial pneumonia
16:00
Breaking the cycle of recurrent C. difficile infections
16:00
Bacterial pneumonia and emerging antibiotic resistance